
    
      Pilot clinical trial on the efficacy and safety of IDRACARE® in moderate to severe symptoms
      of vulvovaginal atrophy. To assess the efficacy and safety of Idracare® in the treatment of
      symptoms of AVV (dryness and / or dyspareunia) associated with menopause.

      Open study with only one arm. The study has a total duration per patient of 3 months: initial
      visit (V1), a follow-up visit (V2) after 4 weeks of treatment and a final visit (V3) after 12
      weeks of treatment.
    
  